DNA Methylation Modulation for CD8 T Cell Exhaustion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches, such as immune checkpoint blockade, have limited success in treating chronic infections and cancers due to T-cell exhaustion, where CD8 T cells become functionally impaired and resistant to rejuvenation, despite antigen reduction or clearance, leading to stabilization of exhaustion-associated gene expression programs.
Innovation Solution
Modulating the DNA methylation status of CD8 T cells to prevent exhaustion and maintain effector functions by identifying and altering specific methylation markers, using demethylation agents or reducing DNA methyltransferase expression to enhance cytokine production and cytotoxic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint blockade therapy is used to treat chronic infections and cancer, then T-cell effector function can be transiently rejuvenated, but the therapy fails when T cells become exhausted and stabilize exhaustion-associated gene expression programs
Solution Approach 1:
The patent applies preliminary action by using DNA demethylating agents (such as 5-azacytidine or 5-aza-2'-deoxycytidine) to treat T cells before they become fully exhausted or before administering checkpoint blockade therapy. This preliminary epigenetic modification prevents the stabilization of exhaustion-associated gene expression programs, thereby maintaining T-cell responsiveness to subsequent immunotherapy interventions.
Solution Approach 2:
The patent changes the epigenetic parameter of DNA methylation status in T cells by administering demethylating agents. This parameter change reverses the hypermethylation of promoter regions associated with effector function genes (such as IFN-γ, IL-2, and granzyme B), thereby restoring gene expression and T-cell functionality without altering the genetic sequence itself.
2Productivity
If T cells are exposed to sustained antigen stimulation during chronic infection, then effector function is initially enhanced, but prolonged stimulation leads to progressive suppression of effector function and T-cell exhaustion
Solution Approach 1:
The patent employs periodic administration of DNA demethylating agents during the course of chronic antigen stimulation. This periodic epigenetic intervention temporarily resets the methylation status of effector function gene promoters, allowing T cells to periodically regain full effector functionality despite continuous antigen exposure, thereby extending functional persistence.
Solution Approach 2:
The patent applies preliminary epigenetic modification to prevent the cumulative effects of prolonged antigen stimulation. By treating T cells with demethylating agents before exhaustion fully sets in, the method preserves effector function genes from becoming permanently silenced, thereby extending the duration of productive T-cell activity during chronic infection.
3Reliability
If DNA methylation status is altered to prevent T-cell exhaustion, then effector function can be maintained during sustained antigen exposure, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent introduces DNA demethylating agents as intermediary compounds that mediate between the problem of antigen-driven T-cell exhaustion and the desired outcome of maintained effector function. These small molecule agents (such as 5-azacytidine) serve as convenient intermediaries that can be administered systemically to achieve epigenetic modification without requiring complex genetic engineering or cell manipulation procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the prediction and modulation of T-cell activity, increasing the effectiveness of immune responses in chronic infections and cancer treatments by maintaining T-cell effector functions and enhancing the responsiveness to immunotherapy.
Implementation Method 1
Altering the methylation status of CD8+ T cells can prevent T-cell exhaustion and maintain effector functions during sustained antigen exposure
Data Source
AI summary
Provided herein are methods and compositions for modulating T-cell activity by altering DNA methylation status. Altering the methylation status of CD8+ T cells can prevent T-cell exhaustion and maintain effector functions during sustained antigen exposure. The methods and compositions can be used to treat symptoms of chronic infections and cancer. Further, the methods and compositions relate to predicting T-cell activity by measuring the methylation status of specific memory cell methylation markers and using the markers to identify and separate populations of CD8 T cell having desired T cell activity. The memory cell methylation markers can further be used to identify subjects with chronic infections or cancer that would benefit from personalized therapy, including immune checkpoint blockade therapy.